Sánchez-Heras, Ana Beatriz http://orcid.org/0000-0003-1742-5374
Dámaso, Estela
Castillejo, Adela
Robledo, Mercedes
Teulé, Alexandre
Lázaro, Conxi
Sánchez-Martínez, Rosario
Zúñiga, Ángel
López-Fernández, Adrià
Balmaña, Judith
Robles, Luis
Ramon y Cajal, Teresa
Castillejo, M. Isabel
Ibañez, Raquel Perea
Sevila, Carmen Martínez
Sánchez-Mira, Andrea
Escandell, Inés
Gómez, Luís
Berbel, Pere
Soto, José Luis
Funding for this research was provided by:
Sociedad Española de Oncología Médica (SEOM+1 grant (UGP-19-428))
Article History
Received: 22 September 2022
Accepted: 11 January 2024
First Online: 26 January 2024
Declarations
:
: This study was approved by the Research Ethics Committee of the Hospital General Universitario de Elche on January 25, 2018 (code 42/2017).
: Not applicable.
: Authors had no relevant conflicts of interest to this matter. Ana Beatriz Sanchez-Heras COI are: Consulting or Advisory Role (Clovis), Speakers' Bureau (AstraZeneca Spain; MSD; GlaxoSmithKline; Clovis), congress registration (MSD; GSK).